Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria CA, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yellala A, Yeung KT, Young JS, Schonfeld R, Kumar R. Gradishar WJ, et al. Among authors: stringer reasor em. J Natl Compr Canc Netw. 2025 Nov;23(11):426-436. doi: 10.6004/jnccn.2025.0053. J Natl Compr Canc Netw. 2025. PMID: 41213254
Prognostic value of visually and computationally-assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030).
Nader-Marta G, Chu X, Mukhopadhyay S, Abramson VG, Brufsky A, Stringer-Reasor EM, Dent SF, Traina TA, Carey LA, Rimawi MF, Specht JM, Miller KD, Santa-Maria CA, Dasgupta T, Kurt BB, DeMeo M, Krop IE, Tung NM, Schnitt SJ, Tayob N, Mayer EL. Nader-Marta G, et al. Among authors: stringer reasor em. J Natl Cancer Inst. 2025 Oct 11:djaf289. doi: 10.1093/jnci/djaf289. Online ahead of print. J Natl Cancer Inst. 2025. PMID: 41075163
EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial).
Hennessy MA, Gatsonis C, Jacene H, Connolly RM, Burnette BL, Stringer-Reasor EM, Romanoff J, Taurone A, O'Sullivan CC, Le-Petross HT, Stearns V, Fowler AM, Tang SC, Sepulveda KA, DeMichele AM, Mankoff DA, Wolff AC. Hennessy MA, et al. Among authors: stringer reasor em. Future Oncol. 2025 Nov;21(26):3377-3384. doi: 10.1080/14796694.2025.2567840. Epub 2025 Oct 5. Future Oncol. 2025. PMID: 41047708 Clinical Trial.
Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancer.
Stringer-Reasor EM, Saha P, Kocherginsky M, Lastra R, Baker G, Lenygel E, Karrison T, Olalde L, Mokrzycki E, Hahn OM, Hoffman PC, Conzen SD, Fleming GF, Nanda R. Stringer-Reasor EM, et al. Breast Cancer Res Treat. 2025 Oct;213(3):347-354. doi: 10.1007/s10549-025-07783-7. Epub 2025 Aug 8. Breast Cancer Res Treat. 2025. PMID: 40779028 Free PMC article. Clinical Trial.
Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy.
Layman RM, Han HS, Rugo HS, Stringer-Reasor EM, Specht JM, Dees EC, Kabos P, Suzuki S, Mutka SC, Sullivan BF, Gorbatchevsky I, Wesolowski R. Layman RM, et al. Among authors: stringer reasor em. Lancet Oncol. 2025 Jul;26(7):e332-e333. doi: 10.1016/S1470-2045(25)00236-0. Lancet Oncol. 2025. PMID: 40609573 No abstract available.
NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer.
Braunstein LZ, Mitchell MP, Bandos H, Sikov WM, Khan AJ, Chen PY, Ganz PA, Jagsi R, White JR, Cecchini RS, Kang H, Puhalla SL, Bolton KL, Connolly EP, Stringer-Reasor EM, Gergelis KR, Julian TB, Mamounas EP, Wolmark N. Braunstein LZ, et al. Among authors: stringer reasor em. Future Oncol. 2025 Jul;21(16):2017-2025. doi: 10.1080/14796694.2025.2511586. Epub 2025 Jun 26. Future Oncol. 2025. PMID: 40574381
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.
Chen N, Matossian M, Saha P, Rampurwala M, Kamaraju S, Hahn O, Howard FM, Fleming GF, Freeman JQ, Karrison T, Conzen S, Nanda R, Stringer-Reasor EM. Chen N, et al. Among authors: stringer reasor em. Breast Cancer Res Treat. 2025 May;211(1):111-119. doi: 10.1007/s10549-025-07626-5. Epub 2025 Feb 10. Breast Cancer Res Treat. 2025. PMID: 39928262 Free PMC article. Clinical Trial.
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria C, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yeung KT, Young JS, Schonfeld R, Kumar R. Gradishar WJ, et al. Among authors: stringer reasor em. J Natl Compr Canc Netw. 2024 Jul;22(5):331-357. doi: 10.6004/jnccn.2024.0035. J Natl Compr Canc Netw. 2024. PMID: 39019058
ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer.
Schneider BP, Zhao F, Ballinger TJ, Garcia SF, Shen F, Virani S, Cella D, Bales C, Jiang G, Hayes L, Miller N, Srinivasiah J, Stringer-Reasor EM, Chitalia A, Davis AA, Makower DF, Incorvati J, Simon MA, Mitchell EP, DeMichele A, Miller KD, Sparano JA, Wagner LI, Wolff AC. Schneider BP, et al. Among authors: stringer reasor em. J Clin Oncol. 2024 Aug 20;42(24):2899-2907. doi: 10.1200/JCO.24.00526. Epub 2024 Jun 3. J Clin Oncol. 2024. PMID: 38828938 Free PMC article.
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Lynce F, et al. Among authors: stringer reasor em. Nat Commun. 2024 May 10;15(1):3957. doi: 10.1038/s41467-024-48359-1. Nat Commun. 2024. PMID: 38730268 Free PMC article. No abstract available.
23 results